James I. Healy, M.D., Ph.D.

Chairman of the Board

Dr. Healy is a General Partner at Sofinnova Ventures. Dr. Healy has over 15 years of experience in biomedical research and development. He joined Sofinnova Ventures as a General Partner in 2000. Dr. Healy was an early investor and board member of Cellective (acquired by MedImmune), CoTherix (acquired by Actelion), Novacea (Nasdaq: NOVC), and InterMune (Nasdaq: ITMN). He also serves on the boards of directors of several private companies.

In the pharmaceutical industry, he held a manufacturing position at Bayer Pharmaceuticals (Miles) and helped guide the discovery group at ISTA Pharmaceuticals prior to its initial public offering. Dr. Healy authored or co-authored numerous research articles and reviews, including three papers published in Nature. He began his private equity career at Sanderling.

Dr. Healy earned B.A.s in Molecular Biology and Scandinavian Studies from the University of California at Berkeley, where he graduated with Distinction in General Scholarship, Honors, and received a Departmental Citation. Dr. Healy received his M.D. from Stanford University’s School of Medicine through the Medical Scientist Training Program, and earned his Ph.D. in Immunology from Stanford University, where he was a Beckman Scholar and received a bursary award from the Novartis Foundation. Dr. Healy teaches a course on entrepreneurship at Stanford University, and is an active member of the BIO-NVCA Working Group.

You are now leaving this website. If you would like to continue, click Continue.